Drug

Sichuan Biokin's HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen
ADC / XDCBiokin Pharmaceutical

Sichuan Biokin’s HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the first patient has recently been dosed in a randomized, controlled phase III clinical trial evaluating its self‑developed T‑Bren (HER2 ADC)…

Henlius' Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China's Bone Health Market

Henlius’ Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China’s Bone Health Market

AstraZeneca's Etcamah (Camizestrant) Misses SERENA‑4 Primary PFS Endpoint in First‑Line Advanced Breast Cancer – Next‑Generation Oral SERD Falls Short Against Anastrozole Plus Palbociclib

AstraZeneca’s Etcamah (Camizestrant) Misses SERENA‑4 Primary PFS Endpoint in First‑Line Advanced Breast Cancer – Next‑Generation Oral SERD Falls Short Against Anastrozole Plus Palbociclib

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
ADC / XDCClinical trial approval / initiation

Gan & Lee’s Nectin-4 ADC GLR1059 Clears Regulatory Hurdle for Solid Tumor Trials

Clinical trial approval / initiationHKG: 9887

Leads Biolabs Enrolls First Patient in Phase II Trial for Gastric Cancer Drug Opamtistomig

Roche's Gazyva Gains FDA Review Acceptance for Systemic Lupus Erythematosus Treatment
OTCMKTS: RHHBYRoche

Roche’s Gazyva Gains FDA Review Acceptance for Systemic Lupus Erythematosus Treatment

Daiichi Sankyo and AstraZeneca Launch Datroway ADC in China for HR-Positive, HER2-Negative Breast Cancer
ADC / XDCAstraZeneca

Daiichi Sankyo and AstraZeneca Launch Datroway ADC in China for HR-Positive, HER2-Negative Breast Cancer

Show More